Welcome to the international HTA database

Showing [18582 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2009	Committee for New Health Technology Assessment (CNHTA)	[Anti-Heparin/Platelet Factor 4 antibody assey]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Anti-GD2 immunotherapy in patients with high risk neuroblastoma]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Anti-d immunoglobulin in pregnancy and immune thrombocytopenia]
2012	Institut national d'excellence en sante et en services sociaux (INESSS)	[Anti-angiogenic drugs in the treatment for age-related macular degeneration: issues associated with their use in Québec]
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Annual Report 2010. German version.]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Angioplasty with stent placement in patients with deep vein thrombosis]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Angioplasty with stent placement in patients with carotid artery disease]
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Angiographic profile of patients undergoing drug eluting stent implantation in Spain. Variability of off-label indications]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Angiogenesis inhibitors (bevacizumab - ranibizumab) in neovascular glaucoma and corneal neovascularization]
2013	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Analytic Hierarchy Process (AHP): pilot project to elicit patient preferences in the indication "depression"]
2001	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of tuberculosis isolation and prophylaxis techniques at a hospital level]
2001	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the use of simple cranium, chest and abdomen radiology in emergency hospital services]
2000	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the use of clinical protocols for monitoring the chronically ill in primary health care]
2013	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the status, systematic review and validation of a diagnostic algorithm for pulmonary thromboembolism (PTE) in the hospital emergency services of the Basque Health Service]
2000	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the scientific evidence on the effectiveness and efficiency of different kinds of hip prosthesis. Recommendations]
2005	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the evolution of main causes of mortality in 65 and older people in the Basque Country (1986-2001)]
1999	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the efficiency of the laboratory test in emergency care]
2017	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the efficacy, safety and efficiency of stabilisation of intervertebral discs using Discogel]
1998	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the efficacy of the treatments and costs of Alzheimer's disease in the Basque Country]
1996	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the cost-effectiveness of the non-mydriatic retinal camera for diabetic retinopathy]
2001	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the appropriateness of hospital admissions from emergencies]
2009	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the adequacy of diagnostic indications of the following application techniques of cerebral MR: MR spectroscopy, diffusion, gadolinum perfusion and cerebral functional-activation MR in advanced neurological diagnosis]
2008	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of telemedicine applications in the management-coordination of specialized and primary care. Appraisal of results and costs of pre-existing experiences (teleophthalmology)]
2001	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of surgical antibiotic prophylaxis]
2007	Andalusian Health Technology Assessment Area (AETSA)	[Analysis of RET mutations to perform prophylactic thyroidectomy in individuals at risk for medullary thyroid cancer]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Analysis of health and socioeconomic factors influencing the progressive increase in frequentation of hospital emergency services]
2011	The Swedish Council on Health Technology Assessment (SBU)	[Analysis of fetal DNA in maternal blood: non-invasive fetal diagnostic tests for blood group and sex determination]
2006	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Analysis of factors that can influence the levels of TSH in the neonatal period]
2017	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Analysis of clinical studies of medical devices]
2008	Andalusian Health Technology Assessment Area (AETSA)	[Analysis of APC mutations to perform prophylactic colectomy in subjects at risk for colorectal cancer]
2014	National Evidence-based Healthcare Collaborating Agency (NECA)	[Analysis for healthcare safety management system]
2001	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis and review of protocols and quality standards in the diagnostic process for the detection of cervical cancer]
2011	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis and development of preventive activities in primary care. Review of the preferential offer and its support software (PAP)]
2016	The Swedish Council on Health Technology Assessment (SBU)	[Anal sphincter injuries]
2016	Basque Office for Health Technology Assessment (OSTEBA)	[An image-guided system for liver surgery (CAScination)]
1998	Andalusian Health Technology Assessment Area (AETSA)	[An evidence-based guideline on unstable angina management]
2015	Basque Office for Health Technology Assessment (OSTEBA)	[An evaluation of the efficacy of psychosocial techniques (cognitive rehabilitation vs. psychoeducation) as an additional treatment to pharmacological treatment in bipolar disorder]
2014	Basque Office for Health Technology Assessment (OSTEBA)	[An evaluation of intensity-modulated radiotherapy (IMRT)]
2007	Andalusian Health Technology Assessment Area (AETSA)	[AmpliChip CYP450: Cytochrome P450 genotyping in psychiatric patients]
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Amotosalen (Intercept) for the inactivation of pathogens for transfusion therapy]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Amifampridine (Firdapse) for the treatment of Lambert Eaton Myasthenic Syndrome]
2009	Committee for New Health Technology Assessment (CNHTA)	[AMH]
1998	Basque Office for Health Technology Assessment (OSTEBA)	[Ambulatory ultrasound in Basque country: current status, recommendations on its use and practice]
2009	Committee for New Health Technology Assessment (CNHTA)	[Ambulatory esophageal multichannel impedence pH monitoring]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Ambrisentan (Volibris) in the treatment of pulmonary arterial hypertension]
2013	Basque Office for Health Technology Assessment (OSTEBA)	[Alternatives to short stay psychiatric hospitalisation. Intensive ambulatory monitoring programmes]
2001	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Alternatives to blood transfusion]
2015	Norwegian Institute of Public Health (NIPH)	[Alternatives of plasma for transfusion to patients]
2015	Haute Autorite de sante (HAS)	[Alternative(s) to 99mTc-sestamibi preoperative scintigraphy for the localization of hypersecreting parathyroid glands in the event of complete shortage of 99mTechnetium (99mTc)]
2012	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Alternative methods for the treatment of post-menopausal troubles]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Alprostadil for nonrevascularizable critical lower limb ischemia]
2008	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Alpha1 antitrypsin]
2012	Andalusian Health Technology Assessment Area (AETSA)	[Allomap genetic test for cardiac transplant rejection]
2009	Committee for New Health Technology Assessment (CNHTA)	[Allo skin graft]
1999	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Allergic diseases: suggestions concerning organization of prevention, diagnostics and treatment (funded by DIHTA)]
2012	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Aliskiren/amlodipine (combination of active ingredients) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Alirocumab for patients with hypercholesterolemia]
2016	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Alirocumab - benefit assessment according to §35a Social Code Book V]
2016	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Alirocumab - addendum to commission A15-47]
2015	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Alipogene tiparvovec - assessment according to §35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Alglucosidase alpha (Myozyme) for treatment of patients with late-onset Pompe disease]
2014	Andalusian Health Technology Assessment Area (AETSA)	[Alglucosidase alfa (Myozyme ®) in late-onset Pompe disease]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Alemtuzumab in multiple sclerosis]
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	[Alemtuzumab for multiple sclerosis]
2003	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Alefacept (Amevive(R)) for the treatment of severe psoriasis]
2017	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Alectinib (NSCLC) - benefit assessment according to §35a Social Code Book V]
2017	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Alectinib (non-small-cell lung cancer) - addendum to commission A17-19]
2016	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Albutrepenonacog alfa - assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2009	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Albumin Dialysis and Molecular Adsorbent Recirculating System (MARS) in the treatment of liver failure]
2011	Haute Autorite de sante (HAS)	[Albumin (or protein) to creatinine ratios in the diagnosis of chronic kidney disease in adults]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Albiglutide - benefit assessment according to section 35a Social Code Book V (dossier assessment)]
2008	Committee for New Health Technology Assessment (CNHTA)	[AGL gene, mutation[sequencing]]
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Age-related macular degeneration: the role of current treatment strategies]
2013	Institute for Clinical Effectiveness and Health Policy (IECS)	[Aflibercept for age-related macular degeneration and central retinal vein occlusion]
2013	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Aflibercept (Zaltrap) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Aflibercept (new therapeutic indication) – benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Aflibercept (new therapeutic indication) - benefit assessment according to §35a Social Code Book V]
2013	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Aflibercept (Eylea) extension of approval: benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Aflibercept (extension of approval) - benefit assessment according to section 35a Social Code Book V (dossier assessment)]
2015	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Aflibercept (Addendum to Commission A14-32)]
2013	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Aflibercept - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Afatinib: benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Afatinib: benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Afatinib (new therapeutic indication) - benefit assessment according to §35a Social Code Book V]
2016	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Afamelanotide - assessment according to §35a (para. 1, sentence 10) Social Code Book V]
2013	Institut national d'excellence en sante et en services sociaux (INESSS)	[Advisability of expanding the Québec newborn blood screening program]
2016	National Evidence-based Healthcare Collaborating Agency (NECA)	[Advantages of vestibular rehabilitation on the vestibular neuritis]
2008	Committee for New Health Technology Assessment (CNHTA)	[Adenovirus, nested PCR]
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Addendum to the notice on the efficacy of rehabilitative interventions and pharmacological therapies for children aged 2 to 12 Years with autism spectrum disorder (ASD)]
2011	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to the final report A09-02 (benefit assessment of prasugrel)]
2015	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A14-26 (empagliflozin)]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A14-21 (fingolimod)]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A14-19 (mirabegron)]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A14-18 (simeprevir)]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to commission A14-14 (dimethyl fumarate)]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A14-12 (canagliflozin)]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to commission A14-05 (sofosbuvir)]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A13-44 (ipilimumab)]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A13-37 (regorafenib)]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A13-35 (dabrafenib)]